strategic alternatives
Viracta Therapeutics Shuts Down Operations, Lays off All Staff
The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.
Viracta Therapeutics Closing Pivotal Nana-Val Trial, Exploring Strategic Alternatives
The company said it is having discussions to explore strategic alternatives, such as a merger, licensing agreements, or a sale, with the goal of maximizing value.
Octernal Stopping Clinical Testing, Reducing Workforce After Safety, Efficacy Issues in Two Trials
The company said it will lay off approximately 37 percent of its workforce and stop all clinical development as it explores strategic alternatives.